ÂÜÀòÂÒÂ×

Mr. Krognes joined the argenx Board of Directors in February 2023 as a non-executive director and chairperson of the audit and compliance committee. Mr. Krognes also serves on the boards of directors of Guardant Health, Denali Therapeutics, and Gritstone bio. He previously served on the board of directors of RLS Global and Corvus.

Mr. Krognes was the chief financial officer of Denali Therapeutics from 2015 until retiring from that position in April 2022. He joined Denali as the founding chief financial officer, building and leading the finance team as well as supervising the IT and facilities functions. He led several successful financings including the initial public offering in 2017 and contributed significantly to the company’s strategy, growth and strong financial position.

His extensive leadership experience in the biotech and pharmaceutical industry includes 12 years at Roche and Genentech serving as chief financial officer of Genentech for six years and global head of Roche’s mergers & acquisition team for six years. He chaired the Genentech Access to Care Foundation and represented Genentech on the board and executive committee of the California Life Science Association.

Before that, he worked as an investment banker at Goldman Sachs, as a management consultant at McKinsey & Company, and as a venture capitalist in Scandinavia. Mr. Krognes holds a master’s in business administration (MBA) from Harvard Business School and a Bachelor of Science in economics from the Wharton School of the University of Pennsylvania.